Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 183 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT07223697RecruitingPhase 2
Long-term safety of Afimkibart for eczema patients
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Los Angeles, CaliforniaAges 18 years+ - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07746427Recruiting
Mindfulness meditation for teens with eczema
This study tests whether a smartphone-based mindfulness meditation program can help teenagers with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams. Participants will learn relaxation techniques to possibly reduce itching and skin inflammation.
New York, New YorkAges 12–17 - NCT06244212Recruiting
Atopic dermatitis treatment with steroid cream trial
This trial tests a common steroid cream (triamcinolone) for atopic dermatitis (a type of eczema). It aims to see how well it works in people who have active skin inflammation and can come back for a follow-up visit one week later.
Winston-Salem, North CarolinaAges 9 years+ - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT07730788Recruiting
Skin imaging study in eczema patients receiving nemolizumab
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
Romans-sur-Isère, DrômeAges 18 years+ - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT06899204Recruiting
Abrocitinib for atopic dermatitis after biologic therapy
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
San Diego, CaliforniaAges 12 years+ - NCT03549416Recruiting
BioDay Registry collects information on new eczema treatments
This registry study collects questionnaire information from people with atopic dermatitis (eczema) who are starting newer whole-body (systemic) treatments. It may help doctors better understand how these new options work in everyday care.
Nijmegen, GelderlandAges birth+ - NCT04170244Recruiting
Skin microbiome study in atopic dermatitis and psoriasis
This study looks at the skin’s germs (“microbiome”) in people with atopic dermatitis (eczema) or psoriasis. It may help researchers better understand what’s going on on the skin and how that might relate to disease severity.
Rochester, New YorkAges 13 years+ - NCT04240522Recruiting
Long-term study of eczema and related allergies
This observational study follows people with eczema (atopic dermatitis) and sometimes related allergies over time, even if they keep their usual medical treatments. It may help researchers better understand how these conditions change and what factors relate to symptoms.
Zurich, Canton of ZurichAges 1–85 - NCT04826744Recruiting
Atopic dermatitis study tracking eyelid involvement
This study looks at how often the eyelids are affected in adults with atopic dermatitis (a long-term skin condition). It may help doctors better understand patterns of skin and eyelid symptoms so care can be improved.
LilleAges 18 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT05285839RecruitingPhase 4
Dupixent plus UVB light for moderate to severe eczema
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
East Windsor, New JerseyAges 18 years+ - NCT05391061Recruiting
Cibinqo tablet study for moderate-to-severe atopic dermatitis
This study looks at Cibinqo (an oral medicine) in people with moderate-to-severe atopic dermatitis (eczema) who are already going to start it under their clinician’s standard care plan. It may help doctors learn about how the medicine works and fits into real-world treatment.
SeoulAges 12 years+ - NCT05995964RecruitingPhase 2
Study of two new medicines for eczema
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Birmingham, AlabamaAges 18 years+
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Atopic Dermatitis trials by city
Studies with a site in or near these metro areas.
Atopic Dermatitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 183 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.